Coverage of Acinetobacter baumannii
For empiric coverage of multidrug-resistant Acinetobacter baumannii, use a polymyxin (colistin or polymyxin B) as the backbone, but only in specific high-risk scenarios: during an outbreak, in endemic settings, or in previously colonized patients. 1
When to Provide Empiric Coverage
Empiric A. baumannii coverage is not universally indicated. Target coverage only when:
- Active outbreak of A. baumannii in your unit
- Endemic situation with high local prevalence
- Prior colonization with A. baumannii (especially carbapenem-resistant strains)
- High colonization pressure in the ICU environment
Risk factors supporting empiric coverage include: prior colonization, immunosuppression, prolonged ICU stay, mechanical ventilation, previous carbapenem or 3rd generation cephalosporin use, and multiple invasive procedures 1.
Empiric Regimen Selection: Algorithm Based on Local Resistance
Low Carbapenem Resistance Areas (<20-30% resistance)
Use carbapenems as first-line:
- Imipenem 0.5-1 g every 6 hours, OR
- Meropenem 2 g every 8 hours (extended infusion preferred) 1
Critical caveat: Carbapenems should NOT be used as monotherapy in areas with high carbapenem resistance rates 1.
High Carbapenem Resistance Areas (Carbapenem-Resistant A. baumannii suspected)
Use polymyxin-based therapy:
Colistin (Polymyxin E):
- Loading dose: 6-9 million IU
- Maintenance: 9 million IU/day in 2-3 divided doses 1
OR Polymyxin B:
- Loading dose: 2-2.5 mg/kg
- Maintenance: 1.5-3 mg/kg/day in 2 doses 1
Important: Polymyxins have the greatest in vitro activity against A. baumannii but carry significant nephrotoxicity risk 1.
What NOT to Use for Empiric Therapy
Do not use as monotherapy empirically:
- Tigecycline (associated with increased mortality in pneumonia and bacteremia) 1, 2
- Sulbactam alone (reserve for directed therapy when MIC ≤4 mg/L) 1
- Cefiderocol (low-certainty evidence against use for CRAB based on CREDIBLE trial showing 49% vs 18% mortality) 2
Combination Therapy Considerations
For severe, high-risk CRAB infections, combination therapy with two in vitro active agents is suggested, though evidence is very low certainty 2.
Avoid these specific combinations:
- Polymyxin-meropenem (strong recommendation against) 2
- Polymyxin-rifampin (strong recommendation against) 2
Exception: If meropenem MIC <8 mg/L, consider high-dose extended-infusion carbapenem as part of combination therapy 2.
Emerging Evidence on Newer Agents
Recent network meta-analyses (2026) suggest:
- Sulbactam-durlobactam shows highest ranking for clinical improvement and microbiological cure, with reduced mortality compared to tigecycline 3, 4
- Cefiderocol-based regimens demonstrated mortality reduction in some analyses 3, 5, but conflicting data exists from the CREDIBLE trial showing worse outcomes in CRAB 2
However, these findings are based on very low certainty evidence, predominantly from observational studies 3.
Directed Therapy After Susceptibilities
Once susceptibilities are known:
If sulbactam MIC ≤4 mg/L:
- Ampicillin-sulbactam 9-12 g/day sulbactam component in 3 doses (4-hour infusion recommended) 1
- Sulbactam may be preferable to colistin due to better safety profile (lower nephrotoxicity and mortality in some studies) 1
If carbapenem-susceptible:
- Use carbapenem monotherapy as directed therapy 1
Critical Safety Considerations
Nephrotoxicity risk hierarchy (highest to lowest):
- Colistin-based regimens (highest risk) 2, 6
- Polymyxin B
- Tigecycline (lowest nephrotoxicity but poor efficacy) 2
Monitor renal function closely with polymyxin use; nephrotoxicity occurred in 33% with colistin vs 15.3% with sulbactam in comparative studies 1.
Common pitfall: Indiscriminate polymyxin use drives further resistance and exposes patients to unnecessary toxicity. Reserve for truly high-risk scenarios only 1.